2019 Annual MarkVCID Conference
MarkVCID 2019 Annual Conference Attendees
June 17, 2019
The MarkVCID Consortium held its third annual conference at the Massachusetts General Hospital, Charlestown campus in June 2019. External advisors, NINDS and consortium site representatives came together from across the country to discuss the development of 11 imaging and fluid-based biomarker kits and consortium operations. Leaders outlined the steps for multi-site testing and implementation, and goals for the upcoming year including biomarker validation analyses and MarkVCID publications.
Presentations
Introductions & consortium updates
Consortium Progress & Publications
Steve Greenberg, MD, PhD
Phase II Multi-Site Testing & Validation
Rod Corriveau, PhD
Data Management Infrastructure & Operations
Karl Helmer, PhD
Wave 2 kits
MRI Free Water
Arvind Caprihan, PhD
Pauline Maillard, PhD
CSF Stratification
Donna Wilcock, PhD
OCTA Retinal
Vessel Skeleton Density
Amir Kashani, MD, PhD
Plasma Neurofilament Light
Sudha Seshadri, MD
Wave 1 Kit Progress
Plasma Exosome Endothelial Inflammation
Fanny Elahi, MD, PhD
MRI WMH Volume
Charles DeCarli, MD
MRI Arteriolosclerosis
Konstantinos Arfanakis, PhD
Plasma Endothelial Signaling
Joel Kramer, PsyD
MRI WMH Growth/Regression
Gregory Jicha, MD, PhD
MRI Peak Skeletonized Mean Diffusivity
Claudia Satizabal, PhD
MRI Cerebrovascular Reactivity
Hanzhang Lu, PhD
Guest speakers
Mayo Clinic Study of Aging
MarkVCID Collaboration
Ron Petersen, MD, PhD
FDA Biomarker Qualification
Panel Discussion
Billy Dunn, MD & Andreas Jeromin, PhD
IP Considerations
to Bring Kits to Clinic/Public
Diane Bovenkamp, PhD
(l to r) Billy Dunn, FDA; Steve Greenberg, MGH; Andreas Jeromin, Cohen Veterans Biosciences
Joel Kramer, UCSF
(l to r) Arvind Caprihan, UNM; Yang Li, JHU
Konstantinos Arfanakis, Rush/IIT
Sudha Seshadri, CHARGE; Vilmundur Gudnason, IHA
Hanzhang Lu, JHU
Donna Wilcock, UKy
Diane Bovenkamp, BrightFocus Foundation
Greg Jicha, UKy
Fanny Elahi, UCSF
Charlie DeCarli, UCD
(l to r) Steve Greenberg, MGH; Rod Corriveau, NIH; Billy Dunn, FDA; Ron Petersen, Mayo Clinic
Click Here to see the 2018 Annual MarkVCID Conference Page
